Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

EGFR-mutated lung cancer: a paradigm of molecular oncology.

Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B.

Oncotarget. 2010 Nov;1(7):497-514. Review.

2.

Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemia.

Vora HH, Shukla SN, Brahambhatt BV, Mehta SH, Patel NA, Parikh SK, Shah KN, Shah PM.

Asia Pac J Clin Oncol. 2010 Dec;6(4):306-19. doi: 10.1111/j.1743-7563.2010.01322.x. Epub 2010 Oct 19.

PMID:
21114781
3.

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.

Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, Zhan F.

Oncotarget. 2010 May;1(1):22-33.

4.

Discovery and characterization of novel mutant FLT3 kinase inhibitors.

Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, Gray NS, Griffin JD.

Mol Cancer Ther. 2010 Sep;9(9):2468-77. doi: 10.1158/1535-7163.MCT-10-0232. Epub 2010 Aug 31.

5.

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Martelli AM, Evangelisti C, Chiarini F, McCubrey JA.

Oncotarget. 2010 Jun;1(2):89-103. Review.

6.

High transcript level of FLT3 associated with high risk of relapse in pediatric acute myeloid leukemia.

Kang HJ, Lee JW, Kho SH, Kim MJ, Seo YJ, Kim H, Shin HY, Ahn HS.

J Korean Med Sci. 2010 Jun;25(6):841-5. doi: 10.3346/jkms.2010.25.6.841. Epub 2010 May 24.

7.

Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.

Stölzel F, Steudel C, Oelschlägel U, Mohr B, Koch S, Ehninger G, Thiede C.

Ann Hematol. 2010 Jul;89(7):653-62. doi: 10.1007/s00277-009-0889-1. Epub 2010 Jan 30.

PMID:
20119833
8.

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M.

Blood. 2010 Feb 18;115(7):1425-32. doi: 10.1182/blood-2009-09-242859. Epub 2009 Dec 10.

9.

FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.

Jin G, Matsushita H, Asai S, Tsukamoto H, Ono R, Nosaka T, Yahata T, Takahashi S, Miyachi H.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):1001-6. doi: 10.1016/j.bbrc.2009.10.094. Epub 2009 Oct 22.

PMID:
19853583
10.

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.

Schittenhelm MM, Kampa KM, Yee KW, Heinrich MC.

Cell Cycle. 2009 Aug 15;8(16):2621-30. Epub 2009 Aug 24.

PMID:
19625780
11.

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

von Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J.

Cancer Res. 2009 Apr 1;69(7):3032-41. doi: 10.1158/0008-5472.CAN-08-2923. Epub 2009 Mar 24.

12.

Mechanisms of resistance to FLT3 inhibitors.

Chu SH, Small D.

Drug Resist Updat. 2009 Feb-Apr;12(1-2):8-16. doi: 10.1016/j.drup.2008.12.001. Epub 2009 Jan 21. Review.

13.

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, Poon LF, Xie Z, Palaniyandi S, Yu H, Glaser KB, Albert DH, Davidsen SK, Chen CS.

Blood. 2009 Apr 23;113(17):4052-62. doi: 10.1182/blood-2008-05-156422. Epub 2009 Jan 14.

14.

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.

Pratz KW, Cortes J, Roboz GJ, Rao N, Arowojolu O, Stine A, Shiotsu Y, Shudo A, Akinaga S, Small D, Karp JE, Levis M.

Blood. 2009 Apr 23;113(17):3938-46. doi: 10.1182/blood-2008-09-177030. Epub 2008 Nov 24.

15.

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.

Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD.

Blood. 2007 Jun 1;109(11):5011-5. Epub 2007 Feb 15.

16.

ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.

Shankar DB, Li J, Tapang P, Owen McCall J, Pease LJ, Dai Y, Wei RQ, Albert DH, Bouska JJ, Osterling DJ, Guo J, Marcotte PA, Johnson EF, Soni N, Hartandi K, Michaelides MR, Davidsen SK, Priceman SJ, Chang JC, Rhodes K, Shah N, Moore TB, Sakamoto KM, Glaser KB.

Blood. 2007 Apr 15;109(8):3400-8. Epub 2007 Jan 5.

17.
18.

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.

Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D.

Blood. 2007 Feb 15;109(4):1643-52. Epub 2006 Oct 17.

19.

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R, Clark R, Levis MJ, Small D.

Blood. 2006 Nov 15;108(10):3262-70. Epub 2006 Jul 20.

20.

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.

Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, Wang B, Bukofzer GT, Wang YC, Stavropoulos JA, Hartandi K, Niquette AL, Soni N, Johnson EF, McCall JO, Bouska JJ, Luo Y, Donawho CK, Dai Y, Marcotte PA, Glaser KB, Michaelides MR, Davidsen SK.

Mol Cancer Ther. 2006 Apr;5(4):995-1006.

Supplemental Content

Support Center